|
|

This is only a preview of the paper Click here to register and get the full text. Existing members click here to login
|
|
|
Corporate Report For Eli Lilly Instructor: Jerry Thorne Financial Accounting 2103 Spring 2004-April 13th By: Jay McCormack Eli Lilly Corporate Report For 2003 As your Financial Advisor I have taken the liberty to look over your shares in the Eli Lilly Company that you have held for the past 10 years to see if it is a stock worth maintaining in your portfolio. In 2003, the Lilly Corporation has introduced many new drugs with very promising outlooks on the market. The products with the largest key growth are Zyprexa (could be a blockbuster), Humalog, Gemzar, Evista, and Actos.
Approximate Word count = 379 Approximate Pages = 1.5 (250 words per page double spaced)
|
|
|

|
|
|